138 related articles for article (PubMed ID: 19328717)
1. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy.
Zawacki WJ; Walker TG; DeVasher E; Halpern EF; Waltman AC; Wicky ST; Ryan DP; Kalva SP
J Vasc Interv Radiol; 2009 May; 20(5):624-7; quiz 571. PubMed ID: 19328717
[TBL] [Abstract][Full Text] [Related]
2. Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy.
Kriegel I; Cottu PH; Fourchotte V; Sanchez S; Fromantin I; Kirov K; Guillaume A; Pelloquin A; Esteve M; Salmon RJ
Anticancer Drugs; 2011 Nov; 22(10):1020-3. PubMed ID: 21970853
[TBL] [Abstract][Full Text] [Related]
3. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.
Erinjeri JP; Fong AJ; Kemeny NE; Brown KT; Getrajdman GI; Solomon SB
Cancer; 2011 Mar; 117(6):1296-301. PubMed ID: 21381016
[TBL] [Abstract][Full Text] [Related]
4. Outpatient placement of subcutaneous venous access ports reduces the rate of infection and dehiscence compared with inpatient placement.
Pandey N; Chittams JL; Trerotola SO
J Vasc Interv Radiol; 2013 Jun; 24(6):849-54. PubMed ID: 23582442
[TBL] [Abstract][Full Text] [Related]
5. Indwelling central venous access port insertion during bevacizumab-based therapy.
Grenader T; Goldberg A; Verstandig A; Shavit L
Anticancer Drugs; 2010 Aug; 21(7):704-7. PubMed ID: 20517148
[TBL] [Abstract][Full Text] [Related]
6. [Complications associated with the placement of subcutaneous central venous access port devices: reasons for removal and complications observed].
Danno K; Ohnishi T; Watanabe A; Ueda M; Yanagawa T; Kim C; Fujita S; Fujita J; Yoshida T; Tono T; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2404-6. PubMed ID: 23268092
[TBL] [Abstract][Full Text] [Related]
7. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
8. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
9. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
10. Radiologic placement of a low profile implantable venous access port in a pediatric population.
Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
[TBL] [Abstract][Full Text] [Related]
11. Incidence of port site complications in relation to timing of bevacizumab infusion.
Yun J; Baek G; Indorf A; Duong A
J Oncol Pharm Pract; 2024 Apr; ():10781552241245037. PubMed ID: 38689544
[TBL] [Abstract][Full Text] [Related]
12. Complication rates and outcomes of 536 implanted subcutaneous chest ports: do rates differ based on the primary operator's level of training?
Silas AM; Perrich KD; Hoffer EK; McNulty NJ
Acad Radiol; 2010 Apr; 17(4):464-7. PubMed ID: 20060749
[TBL] [Abstract][Full Text] [Related]
13. Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.
Berardi R; Rinaldi S; Santini D; Vincenzi B; Giampieri R; Maccaroni E; Marcucci F; Francoletti M; Onofri A; Lucarelli A; Pierantoni C; Tonini G; Cascinu S
Support Care Cancer; 2015 May; 23(5):1295-302. PubMed ID: 25326782
[TBL] [Abstract][Full Text] [Related]
14. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
15. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer.
Koskas M; Chereau E; Ballester M; Selle F; Rouzier R; Daraï E
Anticancer Res; 2010 Nov; 30(11):4743-7. PubMed ID: 21115934
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis.
Schwarz RE; Groeger JS; Coit DG
Cancer; 1997 Apr; 79(8):1635-40. PubMed ID: 9118051
[TBL] [Abstract][Full Text] [Related]
17. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
Gordon CR; Rojavin Y; Patel M; Zins JE; Grana G; Kann B; Simons R; Atabek U
Ann Plast Surg; 2009 Jun; 62(6):707-9. PubMed ID: 19461291
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of port infections within the first 30 days of placement.
Bamba R; Lorenz JM; Lale AJ; Funaki BS; Zangan SM
J Vasc Interv Radiol; 2014 Mar; 25(3):419-23. PubMed ID: 24581465
[TBL] [Abstract][Full Text] [Related]
19. Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
Tsutsumi S; Fukasawa T; Fujii T; Tabe Y; Kigure W; Asao T; Kuwano H
Hepatogastroenterology; 2012 Jun; 59(116):1079-80. PubMed ID: 22580658
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of traumatic versus spontaneous wound dehiscence after penetrating keratoplasty].
Pahor D
Klin Monbl Augenheilkd; 2013 Aug; 230(8):808-13. PubMed ID: 23959512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
